Michela Rossi
Andrea Del Fattore- Bone Physiopathology Research Unit, Translational Pediatrics and Clinical Genetics Research Division, Bambino Gesù Children’s Hospital, IRCCS, Rome,, Italy
Editorial on the Research Topic
Genetic and molecular determinants in bone health and diseases - volume II
In recent years, advances in genetics, multi-omics technologies, and molecular biology have profoundly transformed our understanding of bone biology. The skeleton is now recognized as a highly dynamic organ whose development, remodeling, and pathological alterations are governed by complex and finely regulated genetic programs and molecular networks (1–3). Large-scale genomic studies have identified hundreds of loci associated with bone mineral density and fracture risk, revealing the polygenic architecture of common skeletal traits and diseases (4, 5). New techniques, such as transcriptomic, proteomic, and metabolomic have enabled the systematic characterization of cellular pathways that regulate osteoblast and osteoclast differentiation, activity, and survival (6, 7). Beyond genetic variation, epigenetic mechanisms and microRNA have emerged as key regulators of skeletal cell fate and function, modulating gene expression in response to development, mechanical loading, aging, and disease-associated factors (8, 9). Importantly, the integration of multi-omics datasets with clinical phenotypes is accelerating the identification of biomarker and the development of targeted and personalized new therapeutic strategies (10, 11).
The Research Topic Genetic and Molecular Determinants in Bone Health and Diseases – Volume II brings together ten contributions that explore bone health and disease through the lenses of genomics, transcriptomics, proteomics, epigenetics, and translational medicine.
Genetic architecture of skeletal disorders
The genetic involvement of rare skeletal disorders is one of the major focuses of this Research Topic.
Najjar et al. addressed the complexity of skeletal dysplasias within a national health system framework, highlighting how genetic heterogeneity underlies the wide clinical spectrum of these rare conditions. Their work describes the importance of integrating molecular diagnostics into routine clinical practice to improve disease classification, prognosis, and patient management.
Similarly, Portales-Castillo et al. reviewed disorders caused by homozygous mutations in PTH1R, a key gene in bone and mineral metabolism. By delineating genotype-phenotype correlations, they provide insights into the molecular mechanisms by which alterations in PTH signaling disrupt skeletal development and homeostasis, paving the way for more targeted therapeutic interventions.
Pagliarosi et al. explored the emerging genetic alterations associated with Gorham-Stout disease, a rare osteolytic disorder with unknown etiology. By integrating available genetic and molecular data, the authors discussed the potential involvement of angiogenic, lymphangiogenic, and osteoclastogenic pathways in progressive bone loss. Their review provides a mechanistic framework for future functional studies and highlights the relevance of molecular genetics in deciphering ultra-rare bone diseases.
In the work of Schembri and Formosa, a focus was performed on the identification of osteoporosis genes using family-based studies. They reviewed the evidence showing how rare, high-impact variants segregating within families can uncover novel genetic determinants that may be missed by population-based genome-wide association studies. Their work reinforces the translational potential of genetic profiling for risk stratification and personalized approaches to osteoporosis prevention and management.
Multi-omics approaches and systems biology
In the work of Wang et al. diabetic sarcopenia was investigated using a proteomic strategy, revealing that dysregulation of autophagy- and apoptosis-related pathways contributes to muscle deterioration in diabetes. Although focused on muscle, their findings are highly relevant to skeletal biology, as these same molecular programs influence osteoblast and osteoclast survival and activity. This study highlights how omics-based profiling can identify shared molecular determinants of musculoskeletal decline and opens new perspectives for integrated therapeutic strategies targeting both muscle and bone in metabolic disease.
Li et al. applied a multi-omics strategy to identify Meteorin-like (Metrnl/IL-41) as a novel regulator of bone metabolism and disease activity in ankylosing spondylitis. By integrating omics approaches the authors demonstrated how inflammatory signaling interfaces with molecular pathways regulating bone remodeling.
The intersection between bone and muscle biology, a growing area of translational relevance, is addressed by Yi et al. in their comprehensive review of osteosarcopenia. By integrating epidemiological data with molecular mechanisms, the authors depict osteosarcopenia as a systemic disorder driven by shared genetic and molecular pathways affecting both tissues. This integrative view exemplifies how molecular insights can redefine clinical syndromes and guide the development of combined therapeutic strategies targeting the bone–muscle unit.
Epigenetics and non-coding RNA regulation
Epigenetic regulation and non-coding RNAs emerge as key determinants of bone health in several contributions.
Lin et al. provided a systematic review of the role of circular RNA and long non-coding RNA (ncRNA) in osteonecrosis of the femoral head. The authors highlighted how these epigenetic regulators modulate key biological processes, including apoptosis, angiogenesis, oxidative stress, and extracellular matrix remodeling. Their work emphasizes the importance of post-transcriptional regulation in skeletal pathology and suggests that ncRNA may represent both diagnostic biomarkers and therapeutic targets.
Moreover, Thakore and Delany examined microRNA-based regulation in growth plate cartilage, focusing on how specific miRNA control chondrocyte proliferation, differentiation, and hypertrophy. By dissecting the molecular mechanisms and downstream targets involved in longitudinal bone growth, the authors illustrated the central role of epigenetic regulation in skeletal development. This review also highlights the therapeutic potential of miRNA-based strategies for growth disorders and regenerative medicine.
Genetics and translational implications for clinical practice
Zhou et al. reviewed the association between single nucleotide polymorphisms and susceptibility to osteomyelitis and prosthetic joint infection. Their analysis showed how host genetic variation influences immune responses, inflammatory pathways, and infection risk in skeletal tissues. These findings underscore the relevance of molecular genetics for patient stratification and for developing personalized strategies in orthopedic surgery and infection prevention.
Conclusion
The studies included in this Research Topic demonstrated how genetic and molecular discoveries are increasingly translated into clinical contexts. From rare skeletal disorders to complex conditions such as osteoporosis, the integration of omics technologies, and epigenetic research is reshaping diagnostic and therapeutic paradigms. These contributions highlight the potential of molecular profiling to support precision medicine, enabling earlier diagnosis, refined risk assessment, and the identification of novel therapeutic targets.
Author contributions
MR: Writing – review & editing, Writing – original draft. ADF: Writing – original draft, Writing – review & editing.
Funding
The author(s) declared that financial support was received for this work and/or its publication. MR is supported by the Fondazione Umberto Veronesi. This work was also supported by the Italian Ministry of Health with the “Current Research funds”.
Conflict of interest
The author(s) declared that this work was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
The author ADF declared that they were an editorial board member of Frontiers, at the time of submission. This had no impact on the peer review process and the final decision.
Generative AI statement
The author(s) declared that generative AI was not used in the creation of this manuscript.
Any alternative text (alt text) provided alongside figures in this article has been generated by Frontiers with the support of artificial intelligence and reasonable efforts have been made to ensure accuracy, including review by the authors wherever possible. If you identify any issues, please contact us.
Publisher’s note
All claims expressed in this article are solely those of the authors and do not necessarily represent those of their affiliated organizations, or those of the publisher, the editors and the reviewers. Any product that may be evaluated in this article, or claim that may be made by its manufacturer, is not guaranteed or endorsed by the publisher.
References
1. Karsenty G and Ferron M. The contribution of bone to whole-organism physiology. Nature. (2012) 481:314–20. doi: 10.1038/nature10763
2. Long F. Building strong bones: molecular regulation of the osteoblast lineage. Nat Rev Mol Cell Biol. (2011) 13:27–38. doi: 10.1038/nrm3254
3. Raggatt LJ and Partridge NC. Cellular and molecular mechanisms of bone remodeling. J Biol Chem. (2010) 285:25103–8. doi: 10.1074/jbc.R109.041087
4. Estrada K, Styrkarsdottir U, Evangelou E, Hsu Y, Duncan E, Ntzani E, et al. Genome-wide meta-analysis identifies 56 bone mineral density loci and reveals 14 loci associated with risk of fracture. Nat Genet. (2012) 44:491–501. doi: 10.1038/ng.2249
5. Morris JA, Kemp J, Youlten S, Laurent L, Logan J, Chai R, et al. An atlas of genetic influences on osteoporosis in humans and mice. Nat Genet. (2019) 51:258–66. doi: 10.1038/s41588-018-0302-x
6. Mullin BH, Ribet ABP, and Pavlos NJ. Bone trans-omics: integrating omics to unveil mechanistic molecular networks regulating bone biology and disease. Curr Osteoporos Rep. (2023) 21:493–502. doi: 10.1007/s11914-023-00812-8
7. Uhlén M, Fagerberg L, Hallström B, Lindskog C, Oksvold P, Mardinoglu A, et al. Proteomics. Tissue-based map of the human proteome. Science. (2015) 347:1260419. doi: 10.1126/science.1260419
8. Delgado-Calle J and Riancho JA. The role of DNA methylation in common skeletal disorders. Biol (Basel). (2012) 1:698–713. doi: 10.3390/biology1030698
9. Sharma G, Sultana A, Abdullah KM, Pothuraju R, Nasser MW, Batra SK, et al. Epigenetic regulation of bone remodeling and bone metastasis. Semin Cell Dev Biol. (2024) 154:275–85. doi: 10.1016/j.semcdb.2022.11.002
10. Karasik D and Kiel DP. Evidence for pleiotropic factors in genetics of the musculoskeletal system. Bone. (2010) 46:1226–37. doi: 10.1016/j.bone.2010.01.382
Keywords: bone diseases, bone health, epigenetic, genetic bone diseases, molecular pathways
Citation: Rossi M and Del Fattore A (2026) Editorial: Genetic and molecular determinants in bone health and diseases - volume II. Front. Endocrinol. 17:1789444. doi: 10.3389/fendo.2026.1789444
Received: 16 January 2026; Accepted: 20 January 2026;
Published: 27 January 2026.
Edited and reviewed by:
Ralf Jockers, Université Paris Cité, FranceCopyright © 2026 Rossi and Del Fattore. This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
*Correspondence: Andrea Del Fattore, YW5kcmVhLmRlbGZhdHRvcmVAb3BiZy5uZXQ=